Moderna/Merck partnership and its potential in personalised cancer therapies are good opportunities for long-term investors.

Moderna Inc (MRNA) stock saw a modest uptick, ending the day at $41.58 which represents a slight increase of $2.20 or 5.59% from the prior close of $39.38. The stock opened at $39.71 and touched a low ...

Of the 503 stocks in the S&P 500 (some companies have two classes of stocks that are included) fewer than 30% of them, or 148 ...

It can take several weeks to bounce back after a bout of COVID-19, but some people develop more persistent problems. The ...

A 13-year-old girl in Canada became so sick with H5N1, or bird flu, in late 2024 that she had to be put on a ventilator.

Key Takeaways The S&P 500 fell 0.4% on Tuesday, Dec. 31, 2024, stumbling into the finish line at the end of an upbeat year ...

There’s currently no approved vaccine for norovirus, although Moderna has begun a phase three trial in the U.S. for a vaccine ...

COVID-19 has continued to claim lives at an average rate of about 900 deaths per week in the U.S. over the past year.